Signifor LAR Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Pasireotide

Indications/Uses

Adult patients w/ acromegaly for whom surgery is not an option or has not been curative & who are inadequately controlled on treatment w/ another somatostatin analogue.

Dosage/Direction for Use

IM 40 mg every 4 wk. Patient whose GH &/or IGF-1 levels are not fully controlled after 3 mth of Signifor LAR at 40 mg May increase dose to a max of 60 mg. Moderate hepatic impairment (Child-Pugh B) Initially 20 mg every 4 wk. Max dose: 40 mg every 4 wk.

Contraindications

Severe hepatic impairment (Child-Pugh C).

MIMS Class

Cancer Hormone Therapy

ATC Classification

H01CB05 - pasireotide ; Belongs to the class of antigrowth hormone. Used in hypothalamic hormone preparations.

Regulatory Classification

POM

Presentation/Packing

Form

Signifor LAR powd for susp for inj 20 mg

Packing/Price

1's

Form

Signifor LAR powd for susp for inj 40 mg

Packing/Price

1's

Form

Signifor LAR powd for susp for inj 60 mg

Packing/Price

1's

Signifor LAR

pasireotide

Manufacturer:

Novartis Pharmaceuticals